Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Canopy Growth CorporationNASDAQ: CGC

Change in Working Capital · Q4 FY2025 · quarter ended Mar 2026

Change in working capital growth accelerates

Q4 FY2025 change in working capital of CA$15.16M rose 759.7% year over year, ahead of the +163.3% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -29.5% a year.

Context

  • Change in working capital amounted to 4.3% of revenue in FY2025, down 7.6 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +759.7% holds above the trailing-twelve-month pace of +163.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$15.16M+1045.7% QoQ
Last fiscal yearMar 2026
CA$20.68M+164.7% YoY
LTMMar 2026
CA$20.24M+163.3% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+759.7%——
1 year+164.7%——
3-year CAGR-29.5%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

CAD · from the cash flow

Latest · FY2025
20.68M CAD
Year-over-year change
+164.7%
4-year CAGR
-43.6%

Change in Working Capital vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +163.3% is the highest of 9, against a peer median of -130.6%.
  • Change in working capital amounts to 6.5% of revenue for CGC, versus a peer median of 15.2%.
CGC Competitors
Change in Working Capital for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$70.23M USD-507.4%+141.4%19.4%
DHDefinitive Healthcare Corp.LTM Mar 2026$26.04M USD+79.4%-24.6%10.9%
CGCCanopy Growth CorporationLTM Mar 2026CA$20.24M CAD+163.3%-29.5%6.5%
BIOABioAge Labs, Inc.LTM Mar 2026$10.29M USD-223.3%—99.7%
ACBAurora Cannabis Inc.LTM Mar 2026CA$9.2M CAD-176.3%-28.4%3.0%
CABACabaletta Bio, Inc.LTM Mar 2026$6.7M USD-348.8%-55.5%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$2.98M USD-83.4%—35.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.38M USD+99.5%-28.5%5.7%
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.42M USD-84.9%-50.6%4593.5%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$1.35M USD—+14.8%1.0%
Peer median (excluding CGC) —-130.6%-28.4%15.2%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income(258.91M)(3.08B)(483.68M)(604.14M)(366.64M)
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
Deferred Income Tax(8.95M)(5.73M)12.33M7.14M0
Stock-Based Compensation46.69M25.32M14.18M(4.21M)5.95M
Change in Working Capital205M58.97M3.97M(31.97M)20.68M
Accounts Receivables16.15M6.24M(3.75M)(4.49M)25.69M
Inventory204.22M68.44M1.03M(17.72M)3.71M
Accounts Payables00000
Other Working Capital(15.37M)(15.71M)6.68M(9.77M)(8.72M)
Other Non-Cash Items(640.58M)2.36B118.08M424.3M200.17M
Operating Cash Flow(545.81M)(557.55M)(281.95M)(165.75M)(88.98M)
Capital Expenditures(48.11M)(10.45M)(4M)(11.28M)(7.44M)
Acquisitions (Net)103.2M14.93M(955K)(6.97M)0
Purchases of Investments(379.41M)(67.15M)(347K)(95.34M)0
Sales of Investments546.01M502.59M78.55M16.43M26.5M
Other Investing Activities(2.3M)(7.88M)167.79M48.9M(48.83M)
Investing Cash Flow230.82M433.38M241.59M(47.79M)(29.77M)
Debt Repayment(50.76M)16.98M(509.78M)(220.78M)(24.62M)
Common Stock Issued2.7M1.05M81.06M385.39M374.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.53M(37.72M)(36.34M)(15.96M)114.02M
Financing Cash Flow(45.53M)(19.69M)(465.06M)148.66M463.57M
Effect of Forex Changes(18.12M)44.86M(1.29M)8.39M5.05M
Net Change in Cash(378.65M)(99M)(506.71M)(56.49M)349.86M
Free Cash Flow(593.92M)(568M)(285.95M)(177.03M)(96.42M)

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.